Ticker > Company >

Biofil Chem & Pharma share price

Biofil Chemicals & Pharmaceuticals Ltd.

NSE: BIOFILCHEM BSE: 524396 SECTOR: Pharmaceuticals & Drugs  37k   138   12

62.32
+0.32 (0.52%)
NSE: Today, 10:14 AM

Price Summary

Today's High

₹ 62.44

Today's Low

₹ 60.11

52 Week High

₹ 91.87

52 Week Low

₹ 48.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

101.42 Cr.

Enterprise Value

99.57 Cr.

No. of Shares

1.63 Cr.

P/E

160.21

P/B

5.52

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  11.29

CASH

2.28 Cr.

DEBT

0.44 Cr.

Promoter Holding

46.82 %

EPS (TTM)

₹  0.39

Sales Growth

33.29%

ROE

4 %

ROCE

4.97%

Profit Growth

26.55 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year33.29%
3 Year3.85%
5 Year11.6%

Profit Growth

1 Year26.55%
3 Year-17.02%
5 Year8.02%

ROE%

1 Year4%
3 Year3.84%
5 Year5.6%

ROCE %

1 Year4.97%
3 Year5.32%
5 Year7.65%

Debt/Equity

0.0241

Price to Cash Flow

42.37

Interest Cover Ratio

21.8506

CFO/PAT (5 Yr. Avg.)

0.92086673006385

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 46.82 0.00
Jun 2024 46.82 0.00
Mar 2024 46.82 0.00
Dec 2023 46.82 0.00
Sep 2023 46.82 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 65.5533 days.

 Limitations

  • The company has shown a poor profit growth of -17.0240318042518% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.8453920024631% for the Past 3 years.
  • Company has a poor ROE of 3.8383299804652% over the past 3 years.
  • Company has high debtor days of 244.0235.
  • The company is trading at a high PE of 160.21.
  • The company is trading at a high EV/EBITDA of 82.7069.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 2.43 17.37 5.03 15.2 8.44
Total Expenditure 2.02 17.13 4.84 15.24 8.14
Operating Profit 0.42 0.24 0.19 -0.03 0.31
Other Income 0.03 0.03 0.03 0.41 0.03
Interest 0.01 0.01 0 0.02 0.01
Depreciation 0.11 0.11 0.11 0.08 0.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.32 0.15 0.11 0.27 0.23
Tax 0.08 0.03 0.02 0.03 0.06
Profit After Tax 0.24 0.12 0.09 0.25 0.17
Adjusted EPS (Rs) 0.15 0.08 0.06 0.15 0.1

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 29.69 35.75 22.38 30.04 40.04
Total Expenditure 27.87 34.15 21.05 28.87 39.22
Operating Profit 1.82 1.6 1.33 1.17 0.82
Other Income 0.17 0.8 0.15 0.1 0.49
Interest 0.12 0.07 0.04 0.04 0.04
Depreciation 0.41 0.41 0.43 0.43 0.4
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.46 1.92 1.01 0.79 0.87
Tax 0.26 0.68 0.32 0.23 0.16
Net Profit 1.21 1.24 0.7 0.56 0.71
Adjusted EPS (Rs.) 0.74 0.76 0.43 0.34 0.44

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 16.27 16.27 16.27 16.27 16.27
Total Reserves -1.39 -0.14 0.56 1.03 1.93
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0.36 0.4 0.38 0.36
Current liabilities 27.48 16.75 1.49 13.73 28.52
Total Liabilities 42.36 33.24 18.73 31.41 47.08
Assets
Net Block 10.09 9.78 9.42 9 8.62
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0.05 0.05
Other N/C Assets 0 0 0 0 0
Current Assets 32.27 23.46 9.31 22.35 38.41
Total Assets 42.36 33.24 18.73 31.41 47.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1.46 1.92 1.01 0.79 0.87
Adjustment 0.56 0.48 0.48 0.38 0.63
Changes in Assets & Liabilities -0.87 -0.62 -1.4 -1.05 1.05
Tax Paid -0.25 -0.68 -0.32 -0.23 -0.16
Operating Cash Flow 0.89 1.11 -0.22 -0.11 2.39
Investing Cash Flow -0.21 -0.1 -0.07 -0.01 -0.02
Financing Cash Flow -0.57 -0.83 -0.01 0.02 -0.12
Net Cash Flow 0.12 0.18 -0.3 -0.11 2.25

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 46.82 46.82 46.82 46.82 46.82
cyano finance and sales p... - - - 5.39 5.39
ketan shah 2.83 2.83 2.83 2.83 2.83
kiran shah 0.39 0.39 0.39 0.39 0.39
manali simon - - 0.54 0.54 0.54
meena shah 3.86 3.86 3.86 3.86 3.86
meet shah 0.54 0.54 0.54 0.54 0.54
mid (india) pharmaceutica... - - - 7.22 7.22
niyati shah 1.84 1.84 1.84 1.84 1.84
ramesh shah 3.04 3.04 3.04 3.04 3.04
ritu shah 0.54 0.54 0.54 0.54 0.54
rohan shah 0.40 0.40 0.40 0.40 0.40
romil shah 2.35 2.35 2.35 2.35 2.35
sandeep shah 2.93 2.93 2.40 2.40 2.40
scope finance company pri... 13.90 13.90 13.90 13.90 13.90
smitesh sanalal shah 0.97 0.97 0.97 0.97 0.97
trupti shah 0.63 0.63 0.63 0.63 0.63
cyano finance and sales p... 5.39 5.39 5.39 - -
mid (india) pharmaceutica... 7.22 7.22 7.22 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 53.18 53.18 53.18 53.18 53.18
gom industries ltd 1.11 1.11 1.11 1.11 1.11
jayesh j hapani - - - 1.23 1.23
kishor himmatsinh jhala 1.22 1.22 1.22 1.22 1.22
ksl and industries limite... 1.89 1.89 1.89 1.89 1.89
starline equifin private ... 8.24 8.24 7.58 7.58 7.51

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Biofil Chem & Pharma - Quaterly Results 13 Aug, 6:33 PM Biofil Chem & Pharma - Quaterly Results 13 Aug, 6:33 PM Biofil Chemicals & Pharmaceuticals informs about compliance certificate 3 Apr, 5:29 PM Biofil Chemicals & Pharmaceuticals informs about disclosures 12 Mar, 5:07 PM Biofil Chem & Pharma - Quaterly Results 6 Feb, 8:47 PM Biofil Chem & Pharma - Quaterly Results 6 Feb, 8:47 PM Biofil Chemicals & Pharmaceuticals submits board meeting intimation 1 Nov, 5:08 PM Biofil Chemicals & Pharmaceuticals informs about AGM 2 Sep, 4:15 PM Biofil Chemicals And Pharmaceuticals informs about newspaper publication 24 Aug, 3:03 PM Biofil Chemicals and Pharmaceuticals informs about disclosure 24 May, 4:42 PM Biofil Chemicals & Pharmaceuticals informs about disclosure 22 Feb, 4:42 PM Biofil Chemicals & Pharmaceuticals informs about press release 15 Feb, 5:13 PM Biofil Chem & Pharma - Quaterly Results 9 Aug, 5:57 PM Biofil Chem & Pharma - Quaterly Results 9 Aug, 5:57 PM Biofil Chemicals & Pharmaceuticals informs about details of loss of certificate 7 Jul, 5:31 PM Biofil Chemicals & Pharmaceuticals informs about secretarial compliance report 26 May, 4:50 PM Biofil Chemicals & Pharmaceuticals informs about board meeting 6 Nov, 10:42 AM Biofil Chemicals & Pharmaceuticals informs about revised disclosures 22 Jul, 1:42 PM Biofil Chemicals & Pharmaceuticals informs about clarification 30 Apr, 3:36 PM Biofil Chemicals & Pharmaceuticals informs about issued duplicate share certificates 9 Mar, 1:40 PM Biofil Chemicals & Pharmaceuticals informs about disclosure 7 Jan, 5:04 PM

Biofil Chem & Pharma Stock Price Analysis and Quick Research Report. Is Biofil Chem & Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biofil Chem & Pharma and its performance over the period of time. Biofil Chem & Pharma stock price today is Rs 61.72.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Biofil Chem & Pharma cash from the operating activity was Rs 2.3937 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biofil Chem & Pharma has a Debt to Equity ratio of 0.0241 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biofil Chem & Pharma , the EPS growth was 26.5389 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biofil Chem & Pharma has OPM of 2.03945018521155 % which is a bad sign for profitability.
     
  • ROE: Biofil Chem & Pharma have a poor ROE of 3.995 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Biofil Chem & Pharma is Rs 61.72. One can use valuation calculators of ticker to know if Biofil Chem & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Biofil Chem & Pharma
X